Bayer and Dewpoint Therapeutics sign licensing agreement for heart disease program
- Details
- Category: Bayer
U.S. FDA approves Pfizer's RSV vaccine ABRYSVO® for adults aged 18 to 59 at increased risk for disease
- Details
- Category: Pfizer
Roche's Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
- Details
- Category: Roche
The ELEVATUM study showed clinically meaningful improvement in vision and reduction in retinal fluid in people with diabetic macular edema (DME) treated with Vabysmo who identify as African American, Black, Hispanic and Latino.
Bayer submits EU marketing authorization application for elinzanetant to treat moderate to severe vasomotor symptoms
- Details
- Category: Bayer
Recent survey showed that 67% of European women reported vasomotor symptoms during menopause transition.
Novo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
- Details
- Category: Novo Nordisk
Calquence granted Priority Review in the US for patients with untreated mantle cell lymphoma
- Details
- Category: AstraZeneca
The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventing serious conditions or enhancing patient compliance.
BlueRock Therapeutics' investigational cell therapy bemdaneprocel for Parkinson's disease shows positive data at 24-months
- Details
- Category: Bayer
Bemdaneprocel is the most clinically advanced investigational cell therapy in the U.S. for treating patients living with Parkinson's disease.
More Pharma News ...
- Bayer Co.Lab Shanghai opens as part of global expansion of life science incubator network
- FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosis
- Pfizer highlights diverse oncology oortfolio and combination approaches at ESMO 2024
- Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in oncology
- Pfizer launches PfizerForAll™, a digital platform that helps simplify access to healthcare
- Pfizer and BioNTech provide update on mRNA-based combination vaccine program against influenza and COVID-19 in individuals 18-64 years of age
- Pfizer announces top-line results of ABRYSVO® for RSV in immunocompromised adults